Search

Your search keyword '"Burkart, Madelyn"' showing total 252 results
Start Over Author "Burkart, Madelyn"
252 results on '"Burkart, Madelyn"'

1. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era

Author

Patel, Anand A., Yoon, James J., Johnston, Hannah, Davidson, Marta B., Shallis, Rory M., Chen, Evan C., Burkart, Madelyn, Oh, Timothy S., Iyer, Sunil G., Madarang, Ellen, Muthiah, Chandrasekar, Gross, Iyana, Dean, Raven, Kassner, Joshua, Viswabandya, Auro, Madero-Marroquin, Rafael, Rampal, Raajit K., Guru Murthy, Guru Subramanian, Bradley, Terrence, Abaza, Yasmin, Garcia, Jacqueline S., Gupta, Vikas, Pettit, Kristen M., Cursio, John F., and Odenike, Olatoyosi

Published
2024
Full Text
View/download PDF

3. Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy

Author

Bond, David A, Switchenko, Jeffrey M, Villa, Diego, Maddocks, Kami, Churnetski, Michael C, Gerrie, Alina S, Goyal, Subir, Shanmugasundaram, Krithika, Calzada, Oscar, Kolla, Bhaskar, Bachanova, Veronika, Gerson, James Nathan, Barta, Stefan K, Hill, Brian T, Sawalha, Yazeed, Martin, Peter, Maldonado, Edward, Gordon, Max J, Danilov, Alexey V, Grover, Natalie Sophia, Mathews, Stephanie P, Burkart, Madelyn, Karmali, Reem, Ghosh, Nilanjan, Park, Steven I, Epperla, Narendranath, Badar, Talha, Guo, Jin, Hamadani, Mehdi, Fenske, Timothy S, Malecek, Mary-Kate, Kahl, Brad S, Flowers, Christopher R, Blum, Kristie, and Cohen, Jonathon B

Subjects
Rare Diseases, Prevention, Hematology, Lymphoma, Cancer, Adult, Humans, Lymphoma, Mantle-Cell, Prognosis, Prospective Studies, Recurrence, Treatment Outcome
Abstract

Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) after first-line therapy among 455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive disease during induction or POD within 6 months of diagnosis (n = 65; 14%); POD6-24, defined as POD between 6 and 24 months after diagnosis (n = 153; 34%); and POD>24, defined as POD >24 months after diagnosis (n = 237; 53%). The median overall survival from POD (OS2) was 1.3 years (95% confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD>24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4 years (95% CI 2.1-2.7) for POD>24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

Published
2021

4. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, Atallah, Ehab, Shallis, Rory, Saliba, Antoine N., Patel, Anand, Bewersdorf, Jan P., Grenet, Justin, Stahl, Maximilian, Duvall, Adam, Burkart, Madelyn, Palmisiano, Neil, Bradshaw, Danielle, Kubiak, Michal, Dinner, Shira, Goldberg, Aaron D., Abaza, Yasmin, Murthy, Guru Subramanian Guru, Kota, Vamsi, and Litzow, Mark R.

Published
2023
Full Text
View/download PDF

5. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

Author

Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M., Romancik, Jason T., Kamdar, Manali, Greenwell, I. Brian, Hess, Brian T., Isaac, Krista M., Portell, Craig A., Mejia Garcia, Alex, Goldsmith, Scott, Grover, Natalie S., Riedell, Peter A., Karmali, Reem, Burkart, Madelyn, Buege, Michael, Akhtar, Othman, Torka, Pallawi, Kumar, Anita, Hill, Brian T., Kahl, Brad S., and Cohen, Jonathon B.

Published
2023
Full Text
View/download PDF

6. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Author

Epperla, Narendranath, Switchenko, Jeffrey, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Gordon, Max J., Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Sawalha, Yazeed, Hill, Brian T., Ghosh, Nilanjan, Park, Steven I., Bond, David A., Hamadani, Mehdi, Fenske, Timothy S., Martin, Peter, Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Link, Brian K., Kaplan, Lawrence D., Inwards, David J., Feldman, Andrew L., Hsi, Eric D., Maddocks, Kami, Blum, Kristie A., Bartlett, Nancy L., Cerhan, James R., Leonard, John P., Habermann, Thomas M., Maurer, Matthew J., and Cohen, Jonathon B.

Published
2023
Full Text
View/download PDF

7. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

Author

Abraham, Ivy Elizabeth, Rauscher, Garth H., Patel, Anand Ashwin, Pearse, William B., Rajakumar, Priya, Burkart, Madelyn, Aleem, Ahmed, Dave, Ami, Bharadwaj, Sushma, Paydary, Koosha, Acevedo-Mendez, Maria, Goparaju, Krishna, Gomez, Richard, Carlson, Kylie, Tsai, Stephanie B., Quigley, John G., Galvin, John P., Zia, Maryam, Larson, Melissa L., Berg, Stephanie, Stock, Wendy, Altman, Jessica K., and Khan, Irum

Published
2022
Full Text
View/download PDF

8. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

Author

Alderuccio, Juan Pablo, Olszewski, Adam J., Evens, Andrew M., Collins, Graham P., Danilov, Alexey V., Bower, Mark, Jagadeesh, Deepa, Zhu, Catherine, Sperling, Amy, Kim, Seo-Hyun, Vaca, Ryan, Wei, Catherine, Sundaram, Suchitra, Reddy, Nishitha, Dalla Pria, Alessia, D'Angelo, Christopher, Farooq, Umar, Bond, David A., Berg, Stephanie, Churnetski, Michael C., Godara, Amandeep, Khan, Nadia, Choi, Yun Kyong, Kassam, Shireen, Yazdy, Maryam, Rabinovich, Emma, Post, Frank A., Varma, Gaurav, Karmali, Reem, Burkart, Madelyn, Martin, Peter, Ren, Albert, Chauhan, Ayushi, Diefenbach, Catherine, Straker-Edwards, Allandria, Klein, Andreas, Blum, Kristie A., Boughan, Kirsten Marie, Mian, Agrima, Haverkos, Bradley M., Orellana-Noia, Victor M., Kenkre, Vaishalee P., Zayac, Adam, Maliske, Seth M., Epperla, Narendranath, Caimi, Paolo, Smith, Scott E., Kamdar, Manali, Venugopal, Parameswaran, Feldman, Tatyana A., Rector, Daniel, Smith, Stephen D., Stadnik, Andrzej, Portell, Craig A., Lin, Yong, Naik, Seema, Montoto, Silvia, Lossos, Izidore S., and Cwynarski, Kate

Published
2021
Full Text
View/download PDF

9. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Author

Evens, Andrew M., Danilov, Alexey, Jagadeesh, Deepa, Sperling, Amy, Kim, Seo-Hyun, Vaca, Ryan, Wei, Catherine, Rector, Daniel, Sundaram, Suchitra, Reddy, Nishitha, Lin, Yong, Farooq, Umar, D'Angelo, Christopher, Bond, David A., Berg, Stephanie, Churnetski, Michael C., Godara, Amandeep, Khan, Nadia, Choi, Yun Kyong, Yazdy, Maryam, Rabinovich, Emma, Varma, Gaurav, Karmali, Reem, Mian, Agrima, Savani, Malvi, Burkart, Madelyn, Martin, Peter, Ren, Albert, Chauhan, Ayushi, Diefenbach, Catherine, Straker-Edwards, Allandria, Klein, Andreas K., Blum, Kristie A., Boughan, Kirsten Marie, Smith, Scott E., Haverkos, Brad M., Orellana-Noia, Victor M., Kenkre, Vaishalee P., Zayac, Adam, Ramdial, Jeremy, Maliske, Seth M., Epperla, Narendranath, Venugopal, Parameswaran, Feldman, Tatyana A., Smith, Stephen D., Stadnik, Andrzej, David, Kevin A., Naik, Seema, Lossos, Izidore S., Lunning, Matthew A., Caimi, Paolo, Kamdar, Manali, Palmisiano, Neil, Bachanova, Veronika, Portell, Craig A., Phillips, Tycel, Olszewski, Adam J., and Alderuccio, Juan Pablo

Published
2021
Full Text
View/download PDF

10. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data

Author

Badar, Talha, Szabo, Aniko, Litzow, Mark, Burkart, Madelyn, Yurkiewicz, Ilana, Dinner, Shira, Hefazi, Mehrdad, Shallis, Rory M., Podoltsev, Nikolai, Patel, Anand A., Curran, Emily, Wadleigh, Martha, Balasubramanian, Suresh, Yang, Jay, Arslan, Shukaib, Aldoss, Ibrahim, Mattison, Ryan, Cenin, Danielle, Siebenaller, Caitlin, Advani, Anjali, Liedtke, Michaela, and Atallah, Ehab

Published
2021
Full Text
View/download PDF

12. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin

Author

Badar, Talha, Szabo, Aniko, Wadleigh, Martha, Liedtke, Michaela, Arslan, Shukaib, Siebenaller, Caitlin, Aldoss, Ibrahim, Schultz, Elizabeth, Hefazi, Mehrdad, Litzow, Mark R., Kuo, Eric, Wang, Amy, Curran, Emily, Shallis, Rory M., Podoltsev, Nikolai, Balasubramanian, Suresh, Yang, Jay, Mattison, Ryan, Burkart, Madelyn, Dinner, Shira, Advani, Anjali, and Atallah, Ehab

Published
2020
Full Text
View/download PDF

13. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab

Author

Badar, Talha, Szabo, Aniko, Advani, Anjali, Wadleigh, Martha, Arslan, Shukaib, Khan, Muhammad Ali, Aldoss, Ibrahim, Siebenaller, Caitlin, Schultz, Elizabeth, Hefazi, Mehrdad, Shallis, Rory M., Yurkiewicz, Ilana, Podoltsev, Nikolai, Patel, Anand A., Curran, Emily, Balasubramanian, Suresh, Yang, Jay, Mattison, Ryan J., Burkart, Madelyn, Dinner, Shira, Liedtke, Michaela, Litzow, Mark R., and Atallah, Ehab

Published
2020
Full Text
View/download PDF

14. Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation.

Author

Hantel, Andrew, primary, Wang, Yating, additional, Abraham, Ivy, additional, Patel, Anand Ashwin, additional, Monick, Sarah Elizabeth, additional, Rauscher, Garth H, additional, Avila Rodriguez, Ana Maria, additional, Galvez, Carlos, additional, Doukas, Peter, additional, Altman, Jessica K., additional, Burkart, Madelyn, additional, Erra, Amani, additional, Zia, Maryam, additional, Larson, Melissa L., additional, Dave, Ami Atulkumar, additional, Tsai, Stephanie, additional, Aleem, Ahmed, additional, Raptis, Nepheli, additional, Khan, Irum, additional, and Abel, Gregory A., additional

Published
2024
Full Text
View/download PDF

15. Air Pollutant Impact on Disease Characteristics and Outcomes in Patients with Acute Myeloid Leukemia

Author

Palmer, Andrew Stephen, primary, Rauscher, Garth H, additional, Abraham, Ivy Elizabeth, additional, Burkart, Madelyn, additional, Dave, Ami, additional, Raptis, Nepheli Ioanna, additional, Aleem, Ahmed, additional, Gannamani, Vedavyas, additional, Erra, Amani, additional, Monick, Sarah, additional, Galvez, Carlos, additional, Shah, Syed Abdul Mannan, additional, Rahmani Youshanlouei, Hamed, additional, Larson, Melissa L., additional, Zia, Maryam, additional, Tsai, Stephanie B., additional, Altman, Jessica K., additional, Stock, Wendy, additional, Khan, Irum, additional, and Patel, Anand A, additional

Published
2024
Full Text
View/download PDF

16. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Author

Torka, Pallawi, Kothari, Shalin K., Sundaram, Suchitra, Li, Shaoying, Medeiros, L. Jeffrey, Ayers, Emily C., Landsburg, Daniel J., Bond, David A., Maddocks, Kami J., Giri, Anshu, Hess, Brian, Pham, Luu Q., Advani, Ranjana, Liu, Yang, Barta, Stefan Klaus, Vose, Julie M., Churnetski, Michael C., Cohen, Jonathon B., Burkart, Madelyn, Karmali, Reem, Zurko, Joanna, Mehta, Amitkumar, Olszewski, Adam J., Lee, Sarah, Hill, Brian T., Burns, Timothy F., Lansigan, Frederick, Rabinovich, Emma, Peace, David, Groman, Adrienne, Attwood, Kristopher, and Hernandez-Ilizaliturri, Francisco J.

Published
2020
Full Text
View/download PDF

18. P550: INFLUENCE OF RACE ON COMPLICATIONS OF INTENSIVE CHEMOTHERAPY IN AML

Author

Abraham, Ivy, primary, Rauscher, Garth, additional, Patel, Anand, additional, Monick, Sarah, additional, Burkart, Madelyn, additional, Dave, Ami, additional, Gannamani, Vedavyas, additional, Erra, Amani, additional, Aleem, Ahmed, additional, Raptis, Nepheli, additional, Kroll, Matthew, additional, Zia, Maryam, additional, Tsai, Stephanie, additional, Larson, Melissa, additional, Stock, Wendy, additional, Altman, Jessica, additional, and Khan, Irum, additional

Published
2023
Full Text
View/download PDF

19. P489: PROGNOSTIC IMPACT OF “MULTI-HIT” VERSUS “SINGLE-HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab, additional, Shallis, Rory M., additional, D Goldberg, Aaron, additional, Nanaa, Ahmad, additional, Saliba, Antoine, additional, Patel, Anand, additional, Bewersdorf, Jan, additional, Duvall, Adam, additional, Burkart, Madelyn, additional, Bradshaw, Danielle, additional, Abaza, Yasmin, additional, Stahl, Maximillian, additional, Palmisiano, Neil, additional, Subramanian Guru Murthy, Guru, additional, Kota, Vamsi, additional, Zeidan, Amer M., additional, and Litzow, Mark, additional

Published
2023
Full Text
View/download PDF

21. Allogeneic stem cell transplant improves survival after first- or second-line therapy in TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Author

Badar, Talha, primary, Atallah, Ehab, additional, Shallis, Rory, additional, Saliba, Antoine, additional, Patel, Anand, additional, Bewersdorf, Jan, additional, Grenet, Justin, additional, Stahl, Maximilian, additional, Duvall, Adam, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Bradshaw, Danielle, additional, Kubiak, Michal, additional, Dinner, Shira, additional, Goldberg, Aaron, additional, Abaza, Yasmin, additional, Murthy, Guru Subramanian Guru, additional, Kota, Vamsi, additional, and Litzow, Mark, additional

Published
2022
Full Text
View/download PDF

22. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia

Author

Badar, Talha, primary, Litzow, Mark R., additional, Shallis, Rory M., additional, Patel, Anand, additional, Saliba, Antoine N., additional, Burkart, Madelyn, additional, Bewersdorf, Jan P., additional, Stahl, Maximilian, additional, De Camargo Correia, Guilherme Sacchi, additional, Guru Murthy, Guru Subramanian, additional, Abaza, Yasmin, additional, Duvall, Adam, additional, Bradshaw, Danielle, additional, Kota, Vamsi, additional, Dinner, Shira, additional, Goldberg, Aaron D., additional, Palmisiano, Neil, additional, Al Kali, Aref, additional, and Atallah, Ehab, additional

Published
2022
Full Text
View/download PDF

23. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Author

Epperla, Narendranath, primary, Switchenko, Jeffrey M., additional, Bachanova, Veronika, additional, Gerson, James N, additional, Barta, Stefan K, additional, Gordon, Max J, additional, Danilov, Alexey V, additional, Grover, Natalie Sophia, additional, Mathews, Stephanie P, additional, Burkart, Madelyn, additional, Karmali, Reem, additional, Sawalha, Yazeed, additional, Hill, Brian T., additional, Ghosh, Nilanjan, additional, Park, Steven I, additional, Bond, David A, additional, Hamadani, Mehdi, additional, Fenske, Timothy S., additional, Martin, Peter, additional, Guo, Jin, additional, Malecek, Mary-Kate, additional, Kahl, Brad S., additional, Flowers, Christopher R., additional, Link, Brian K., additional, Kaplan, Lawrence D., additional, Inwards, David J, additional, Feldman, Andrew, additional, Hsi, Eric D., additional, Maddocks, Kami, additional, Blum, Kristie, additional, Bartlett, Namcy L., additional, Cerhan, James R., additional, Leonard, John P., additional, Habermann, Thomas M., additional, Maurer, Matthew J., additional, and Cohen, Jonathon B., additional

Published
2022
Full Text
View/download PDF

24. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab L., additional, Shallis, Rory Michael, additional, Saliba, Antoine N., additional, Stahl, Maximilian F., additional, Bewersdorf, Jan Philipp, additional, Grenet, Justin, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam S, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Kubiak, Michal Jakub, additional, Kota, Vamsi K., additional, Dinner, Shira, additional, Goldberg, Aaron D, additional, and Litzow, Mark R., additional

Published
2022
Full Text
View/download PDF

25. Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Author

Patel, Anand Ashwin, primary, Yoon, James J., additional, Johnston, Hannah, additional, Chen, Evan C., additional, Burkart, Madelyn, additional, Seijung Oh, Timothy, additional, Iyer, Sunil G., additional, Madarang, Ellen, additional, Gross, Iyana, additional, Bradley, Terrence, additional, Abaza, Yasmin, additional, Garcia, Jacqueline S., additional, Shallis, Rory Michael, additional, Guru Murthy, Guru Subramanian, additional, Gupta, Vikas, additional, Pettit, Kristen M., additional, Cursio, John, additional, and Odenike, Olatoyosi, additional

Published
2022
Full Text
View/download PDF

26. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab L., additional, Saliba, Antoine N., additional, Shallis, Rory Michael, additional, Stahl, Maximilian F., additional, Bewersdorf, Jan Philipp, additional, Sacchi De Camargo Correia, Guillerhme, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam S, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Bradshaw, Danielle, additional, Kota, Vamsi K., additional, Dinner, Shira, additional, Goldberg, Aaron D, additional, and Litzow, Mark R., additional

Published
2022
Full Text
View/download PDF

27. Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis

Author

Melody, Megan, primary, Burkart, Madelyn, additional, Villa, Marcelo, additional, Zhu, Fenlu, additional, Winter, Jane N., additional, Karmali, Reem, additional, Lin, Adam Yuh, additional, Gordon, Leo I., additional, Adekola, Kehinde, additional, Moreira, Jonathan, additional, Singhal, Seema, additional, and Mehta, Jayesh, additional

Published
2022
Full Text
View/download PDF

28. Racial disparities in patients with TP53 mutated acute myeloid leukemia.

Author

Badar, Talha, primary, Litzow, Mark Robert, additional, Shallis, Rory, additional, Stahl, Maximilian, additional, Bewersdorf, Jan Philipp, additional, Saliba, Antoine N, additional, Sacchi de Camargo Correia, Guilherme, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam, additional, Burkart, Madelyn, additional, Al-Kali, Aref, additional, Palmisiano, Neil, additional, Dinner, Shira, additional, Goldberg, Aaron David, additional, and Atallah, Ehab L., additional

Published
2022
Full Text
View/download PDF

30. Chemotherapy-Free Regimens Gain Ground in Older Patients With ALL.

Author

Burkart, Madelyn and Wieduwilt, Matthew J.

Subjects
THERAPEUTIC use of antineoplastic agents, IMMUNOTHERAPY, CELLULAR therapy, CANCER chemotherapy, METASTASIS, MONOCLONAL antibodies, LYMPHOBLASTIC leukemia, B cell lymphoma, B cells, OLD age
Published
2024

31. Outcomes ofTP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Author

Badar, Talha, primary, Atallah, Ehab, additional, Shallis, Rory M., additional, Goldberg, Aaron D., additional, Patel, Anand, additional, Abaza, Yasmin, additional, Bewersdorf, Jan P., additional, Saliba, Antoine N., additional, Correia, Guilherme Sacchi De Camargo, additional, Murthy, Guru, additional, Duvall, Adam, additional, Burkart, Madelyn, additional, Stahl, Maximilian, additional, Liu, Yuanhang, additional, Dinner, Shira, additional, Palmisiano, Neil, additional, Litzow, Mark R., additional, and Foran, James M., additional

Published
2022
Full Text
View/download PDF

33. Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma

Author

Roy, Ishan, primary, Smilnak, Gordon, additional, Burkart, Madelyn, additional, Hamilton, Elizabeth, additional, Thorp, Katherine, additional, Miyata, Sarah, additional, Ma, Shuo, additional, Pro, Barbara, additional, Winter, Jane, additional, Gordon, Leo, additional, and Karmali, Reem, additional

Published
2022
Full Text
View/download PDF

35. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia.

Author

Badar, Talha, Litzow, Mark R., Shallis, Rory M., Patel, Anand, Saliba, Antoine N., Burkart, Madelyn, Bewersdorf, Jan P., Stahl, Maximilian, De Camargo Correia, Guilherme Sacchi, Guru Murthy, Guru Subramanian, Abaza, Yasmin, Duvall, Adam, Bradshaw, Danielle, Kota, Vamsi, Dinner, Shira, Goldberg, Aaron D., Palmisiano, Neil, Al Kali, Aref, and Atallah, Ehab

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, BLACK people, HEMATOPOIETIC stem cell transplantation, HEMATOLOGIC malignancies
Abstract

Background: Although the clinical outcomes of patients with TP53‐mutated acute myeloid leukemia (AML) are dismal, subsets of patients eligible for curative‐intent therapies may fare better. Because racial disparities are known to affect outcome in hematologic malignancies, the authors sought to explore disparities among patients with TP53‐mutated AML. Methods: A multicenter, retrospective study was conducted in a cohort of 340 patients who had TP53‐mutated AML (275 non‐Hispanic White [NHW] and 65 non‐Hispanic Black [NHB]) to analyze differences in treatment and outcome among NHW and NHB patients. Results: The median patient age was comparable between NHW and NHB patients (p =.76). A higher proportion of NHB patients had therapy‐related AML (31% vs. 20%; p =.08) and had co‐mutations (74% vs. 61%; p =.06). A higher proportion of NHW patients received intensive chemotherapy compared with NHB patients (47% vs. 31%; p =.02). Conversely, a higher proportion of NHB patients received low‐intensity chemotherapy (9% vs. 5.5%; p =.02) or best supportive care (22% vs. 7%; p <.001). The complete response rate (including complete responses with or without complete count recovery) was 31% versus 24.5% (p =.39) in NHW and NHB patients, respectively. Only 5% of NHB patients received allogeneic stem cell transplantation compared with 15.5% of NHW patients (p =.02). The proportion of patients who were event‐free (18.5% vs. 8.5%; p =.49) or who remained alive (24.9% vs. 8.3%; p =.13) at 18 months was numerically higher in NHW versus NHB patients, respectively, but was not statistically significant. Conclusions: The current study highlights disparities between NHW and NHB patients with TP53‐mutated AML. Efforts are warranted to eliminate treatment disparities in minority populations. Non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia (AML) were more likely to have concurrent mutations and therapy‐related AML than non‐Hispanic White patients. Non‐Hispanic Black patients who had TP53‐mutated AML received disease‐directed therapies less often compared with non‐Hispanic White patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis

Author

Roth, Aleeza J., Ooi, Joshua D., Hess, Jacob J., van Timmeren, Mirjan M., Berg, Elisabeth A., Poulton, Caroline E., McGregor, JulieAnne, Burkart, Madelyn, Hogan, Susan L., Hu, Yichun, Winnik, Witold, Nachman, Patrick H., Stegeman, Coen A., Niles, John, Heeringa, Peter, Kitching, A. Richard, Holdsworth, Stephen, Jennette, J. Charles, Preston, Gloria A., and Falk, Ronald J.

Subjects
Identification and classification, Development and progression, Properties, Vasculitis -- Development and progression, Autoantibodies -- Identification and classification, Antigenic determinants -- Properties
Abstract

Anti-neutrophil cytoplasmic antibody--associated (ANCA-associated) small vessel necrotizing vasculitis is caused by immune-mediated inflammation of the vessel wall and is diagnosed in some cases by the presence of myeloperoxidase-specific antibodies (MPO-ANCA). [...]

Published
2013
Full Text
View/download PDF

37. Outcomes and Predictors of Relapse with Use of Hypomethylating Agents in Combination with Venetoclax Prior to Allogeneic Transplant in Acute Myeloid Leukemia

Author

Nizamuddin, Imran, primary, Seijung Oh, Timothy, additional, Numan, Yazan, additional, Kelsten, Max Farber, additional, Burkart, Madelyn, additional, Frankfurt, Olga, additional, Vigil, Carlos E., additional, Abaza, Yasmin, additional, Altman, Jessica K., additional, and Dinner, Shira, additional

Published
2021
Full Text
View/download PDF

38. Myeloid Sarcoma Reveals a Unique Tumor Micro-Environment and Differential Prognosis Based on Transplant Status and Type of Treatment Received

Author

Numan, Yazan, primary, Tariq, Hamza, additional, Fan, Jie, additional, Xie, Ping, additional, Burkart, Madelyn, additional, Abaza, Yasmin, additional, Chen, Yi-Hua, additional, Dinner, Shira, additional, Frankfurt, Olga, additional, Mehta, Jayesh, additional, Zhang, Hui, additional, Altman, Jessica K., additional, and Zhang, Bin, additional

Published
2021
Full Text
View/download PDF

39. Structural and Social Barriers to Survival in Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML)

Author

Burkart, Madelyn, primary, Abraham, Ivy, additional, Rauscher, Garth, additional, Raptis, Nepheli, additional, Zia, Maryam, additional, Patel, Anand Ashwin, additional, Dave, Ami, additional, Berg, Stephanie, additional, Stock, Wendy, additional, Larson, Melissa L., additional, Pearse, William B, additional, Altman, Jessica K., additional, Khan, Irum, additional, and Dinner, Shira, additional

Published
2021
Full Text
View/download PDF

40. Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Author

Grenet, Justin, primary, Jain, Akriti G, additional, Burkart, Madelyn, additional, Waksal, Julian, additional, Famulare, Christopher, additional, Numan, Yazan, additional, Stahl, Maximilian, additional, Mckinnell, Zoe, additional, Ball, Brian, additional, Ma, Xiaoyue, additional, Christos, Paul J, additional, Ritchie, Ellen, additional, Samuel, Michael B., additional, Kaner, Justin D., additional, Lee, Sangmin, additional, Goldberg, Aaron D, additional, Dinner, Shira, additional, Sweet, Kendra, additional, Roboz, Gail J., additional, and Desai, Pinkal, additional

Published
2021
Full Text
View/download PDF

41. Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Author

Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M., Romancik, Jason T., Kamdar, Manali, Greenwell, Irl Brian, Hess, Brian T., Isaac, Krista, Portell, Craig A., Mejia Garcia, Alex V., Goldsmith, Scott R., Grover, Natalie S, Riedell, Peter A., Karmali, Reem, Burkart, Madelyn, Buege, Michael J, Akhtar, Othman S., Torka, Pallawi, Kumar, Anita, Hill, Brian T., Kahl, Brad S., and Cohen, Jonathon B.

Published
2020
Full Text
View/download PDF

42. Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era

Author

Karmali, Reem, primary, Switchenko, Jeffrey M., additional, Goyal, Subir, additional, Shanmugasundaram, Krithika, additional, Churnetski, Michael C., additional, Kolla, Bhaskar, additional, Bachanova, Veronika, additional, Gerson, James N., additional, Barta, Stefan K., additional, Gordon, Max J., additional, Danilov, Alexey V., additional, Grover, Natalie S., additional, Epperla, Narendranath, additional, Mathews, Stephanie, additional, Burkart, Madelyn, additional, Sawalha, Yazeed, additional, Hill, Brian T., additional, Ghosh, Nilanjan, additional, Park, Steven I., additional, Bond, David A., additional, Maddocks, Kami J., additional, Badar, Talha, additional, Fenske, Timothy S., additional, Hamadani, Mehdi, additional, Guo, Jin, additional, Malecek, Mary, additional, Kahl, Brad S., additional, Martin, Peter, additional, Blum, Kristie A., additional, Flowers, Christopher R., additional, and Cohen, Jonathon B., additional

Published
2021
Full Text
View/download PDF

43. Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis

Author

D’Angelo, Christopher R., primary, Hanel, Walter, additional, Chen, Yi, additional, Yu, Menggang, additional, Yang, David, additional, Guo, Ling, additional, Karmali, Reem, additional, Burkart, Madelyn, additional, Ciccosanti, Colleen, additional, David, Kevin, additional, Risch, Zachary, additional, Murga‐Zamalloa, Carlos, additional, Devata, Sumana, additional, Wilcox, Ryan, additional, Savani, Malvi, additional, Courville, Elizabeth L., additional, Bachanova, Veronika, additional, Rabinovich, Emma, additional, Peace, David, additional, Osman, Fauzia, additional, Epperla, Narendranath, additional, and Kenkre, Vaishalee P., additional

Published
2021
Full Text
View/download PDF

44. Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy

Author

Shaw, Reid, Yoon, James J., Johnston, Hannah, Davidson, Marta B., Siddon, Alexa J., Shallis, Rory M., Chen, Evan C., Burkart, Madelyn, Oh, Timothy S., Iyer, Sunil G., Madarang, Ellen, Muthiah, Chandrasekar, Kassner, Joshua, Rampal, Raajit K., Guru Murthy, Guru Subramanian, Bradley, Terrence, Abaza, Yasmin, Garcia, Jacqueline S., Gupta, Vikas, Pettit, Kristen M., Odenike, Olatoyosi, and Patel, Anand A.

Published
2025
Full Text
View/download PDF

45. Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Author

Abaza, Yasmin, Xie, Zhuoer, Burkart, Madelyn, Badar, Talha, Desai, Pinkal, Shallis, Rory M., Patel, Anand Ashwin, Cohen-Nowak, Adam, Oh, Timothy S., Walker, Chelsea, Easwar, Neela, Kewan, Tariq, Cannova, Joseph, Bell-Burdett, Kirsten, Al Ali, Najla H, Sallman, David A, Roboz, Gail J., Carraway, Hetty E., Zeidan, Amer M., Patnaik, Mrinal M., Altman, Jessica K., and Komrokji, Rami S.

Published
2023
Full Text
View/download PDF

46. Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Author

Patel, Anand Ashwin, Yoon, James J., Johnston, Hannah, Davidson, Marta Beata, Viswabandya, Auro, Shallis, Rory M., Chen, Evan C., Burkart, Madelyn, Oh, Timothy S., Iyer, Sunil G., Madarang, Ellen, Muthiah, Chandrasekar, Dean, Raven, Kassner, Joshua, Rampal, Raajit K., Guru Murthy, Guru Subramanian, Bradley, Terrence, Abaza, Yasmin, Garcia, Jacqueline S., Gupta, Vikas, Pettit, Kristen Marie, Cursio, John, and Odenike, Olatoyosi

Published
2023
Full Text
View/download PDF

48. Individual-Level Social Determinants of Health (SDOH) Measures and Treatment Complications in Acute Leukemia

Author

Shah, Eshana, Avila Rodriguez, Ana Maria, Luo, Jerry W, Cwykiel, Joanna, Chasson, Tasha, Raigoza, Elizabeth, Bratslavsky, Alexander, Doukas, Peter, Williams, Reanna, Jackowicz, Christa, Lee, Hyein, Khan, Talha, Webb, Kimberly, Abaza, Yasmin, Altman, Jessica K., Yanez, Betina, Quigley, John, Galvez, Carlos, Dinner, Shira N., Johnson, Kim, Burkart, Madelyn, and Khan, Irum

Published
2023
Full Text
View/download PDF

49. Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival

Author

Shanmugasundaram, Krithika, primary, Goyal, Subir, additional, Switchenko, Jeffery, additional, Calzada, Oscar, additional, Churnetski, Michael C., additional, Kolla, Bhaskar, additional, Bachanova, Veronika, additional, Gerson, James N., additional, Barta, Stefan K., additional, Gordon, Max J., additional, Danilov, Alexey V., additional, Grover, Natalie S., additional, Mathews, Stephanie, additional, Burkart, Madelyn, additional, Karmali, Reem, additional, Sawalha, Yazeed, additional, Hill, Brian T., additional, Ghosh, Nilanjan, additional, Park, Steven I., additional, Epperla, Narendranath, additional, Bond, David A., additional, Badar, Talha, additional, Blum, Kristie A., additional, Hamadani, Mehdi, additional, Fenske, Timothy S., additional, Malecek, Mary, additional, Kahl, Brad S., additional, Martin, Peter, additional, Guo, Jin, additional, Flowers, Christopher R., additional, and Cohen, Jonathon B., additional

Published
2021
Full Text
View/download PDF

50. Cachexia is an independent factor for negative clinical and functional outcomes in lymphoma patients receiving CART therapy.

Author

Roy, Ishan, primary, Smilnak, Gordon John, additional, Burkart, Madelyn, additional, Williams, Corinne, additional, Hamilton, Elizabeth, additional, Miyata, Sarah, additional, Thorp, Katherine, additional, Ma, Shuo, additional, Winter, Jane N., additional, Pro, Barbara, additional, Gordon, Leo I., additional, and Karmali, Reem, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results